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Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription
(Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an affin-

201.1066 (17), was subjected to computer-aided lead optimiza-

ity (KD) of 504 nM, blocks Stat3-phospho-tyrosine (pTyr) peptide
interactions and Stat3 activation at 4-6.8 цМ, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent

gand that inhibits Stat3 activation and functions in vitro and in
vivo, and thereby inhibits growth of mouse xenografts of human
breast and non-small-cell lung cancers.

tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3
in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bd-xL,
Survivin, VEGF, and Krüppel-like factor 8, which is identified as a
Stat3 target gene that promotes Stat3-mediated breast tumor cell

migration and invasion. Treatment of breast cancer cells with

BP-1-102 further blocks Stat3-NF-icB cross-talk, the release of gran-

ulocyte colony-stimulating factor, soluble intercellular adhesion
molecule 1, macrophage migration-inhibitory factor/glycosylationinhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhe-

sion kinase and paxillin, while enhancing E-cadherin expression.
Intravenous or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of
human breast and lung tumor xenografts.

Signal teins
teins mediate
mediateresponses
transducerto responses
cytokines and activator
growth factors
to cytokines
(1). of transcription and growth (STAT) factors pro- (1).
Recruitment via the Src homology 2 (SH2) domain to receptor
phospho-tyrosine (pTyr) peptide motifs facilitates STAT phosphorylation on a key tyrosyl residue by growth factor receptors
and the Janus kinase (Jak) and Src kinase families. Phosphorylation induces STAT-STAT dimerization through a reciprocal
pTyr-SH2 domain interaction. The active dimers in the nucleus
induce gene transcription by binding to specific DNA-respoñse
elements in the promoters of target genes.
The aberrant activation of Stat3 occurs in many human cancers (2) and promotes tumor progression. The mechanisms of
Stat3-mediated tumorigenesis include dysregulation of gene expression that leads to uncontrolled growth and survival of tumor
cells, enhanced tumor angiogenesis, and metastasis (3, 4). Tumor
cell-associated constitutively active Stat3 also regulates proinflammatory cytokine expression, including RANTES (regulated
upon activation normal T cell expressed and secreted) and CXC
motif chemokine 10 (CXCL10)/IFN-y-induced protein 10 (IP10), and the induction of VEGF, interleukin 10 (IL-10), and
other soluble factors, which in turn activate Stat3 in dendritic
cells and inhibit their maturation. These events suppress tumorimmune surveillance (5). Reports also show Stat3-NF-KB crosstalk that supports the malignant phenotype (6, 7).
Given its importance to cancer, Stat3 is the focus of drug
discovery efforts, and the SH2 domain-pTyr interaction has
gained much attention (2, 8-14). Although several dimerizationdisrupting small-molecule Stat3 inhibitors have been reported
(8, 9, 13-16), thus far none has reached the clinic for several
reasons, including the suitability of the scaffolds and pharmacokinetic issues. The leading dimerization-disrupting agent, S3I-

tion. We describe the derivation and characterization of the

analog, BP-1-102, an orally bioavailable Stat3 SH2 domain li-

Results

Computer-Aided Design of BP-1-102 as an Analog of S3I-201.1066.
Analysis of the structural composition and topology of the Stat3

SH2 domain-binding "hotspot" shows three solvent-accessible

subpockets on the protein surface, including the key pTyr705binding region, which are accessed by S3I-201.1066 and most of
the reported Stat3 inhibitors. BP-1-102 (Fig. L4) has appendages

that promote interactions with all three subpockets (Fig. IS).

Synthesis, chemical characterization, and detailed structural information and further discussion are presented in SI Results, SI
Materials and Methods, and Scheme SI.
Inhibition of Stat3 Signaling and Function. BP-1-102 binds Stat3
with a KD of 504 nM, determined by surface plasmon resonance
(SPR) analysis (Fig. SL4). It preferentially disrupts Stat3 binding

to phosphorylated, native high-affinity, IL-6R/gpl30 peptide
(pTyr, pY904), with an IC50 of 4.1 jiM (Fig. S IB), as determined
by fluorescence polarization (FP) assay, compared with its weaker

activity against Stati binding to the IFN-y receptor peptide
(GpYDKPHVL-NH2) or Stat5 binding to the erythropoietin receptor peptide (GpYLVLDKW-NH2), with an IC50 of 25-30 jiM
(Fig. SIC). Isothermal titration calorimetry (ITC) was further

used to examine BP-1-102 effects on the interaction between

pY904 and Stat3 (Fig. SID). ITC experiments in the absence and
>a
presence of BP-1-102 were conducted using identical sample
О
concentrations and conditions (SI Materials and Methods). оPreи
<
complexing Stat3 with BP-1-102 dramatically alters the pY904
S
oc
profile, with significantly reduced enthalpic contribution by
~6
<
z
kcal/mol (Fig. S ID, Left vs. Right, respective y-axis intercepts).
CL

This result indicates a direct interference of pY904 binding to the
SH2 domain. Similarly, the reverse ITC titration of BP-1-102 into
free or pY904-bound Stat3 (Fig. SIE, Left and Right, respectively)
>

ее
h-

l/t
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Fig. 1. (A) Structure of BP-1-102. ( В ) Computational modeling of BP-1-102
binding to the Stat3 SH2 domain. (Left) Monomer Stat3 with the solventaccessible surface of the SH2 domain (off-white) color-coded with hydro-

philic (blue) and hydrophobic residues (pink) and overlaid with BP-1-102
(cyan). {Right) The three solvent-accessible subpockets of the 5H2 domain
surface accessed by BP-1-102, with the pentafluorobenzene sulfonamide
component projecting into the third subpocket composed of Lys591, Glu594,
Ile634, and Arg595.

confirms that these two ligands interfere with each other's binding

at the SH2 domain. In fact, titration of BP-1-102 to pY904-bound
Stat3 shows an increasing endothermic profile (heat absorption),

consistent with BP-1-102 displacing pY904 from Stat3. Taken
together, these results suggest direct competition of the ligands
to the same binding site on the SH2 domain.
The R2 relaxation filter NMR approach (18) was used to study
pY904 binding to Stat3 and verify that BP-1-102 competes with
pY904. The pY904 signal (Fig. SI F, black tracing) was attenuated
upon addition of Stat3 (Fig. SI F, red tracing), indicating binding.
Addition of BP-1-102 resulted in further attenuation (Fig. S1F,
blue tracing), suggesting direct interference with pY904 binding
to the SH2 domain. The interference could be more significant if

BP-1-102 did not form soluble aggregates in the aqueous environment used for NMR studies (Fig. SI G and SI Materials and
Methods). This result further supports the findings by SPR, FP,
and ITC. BP-1-102 inhibits Stat3 DNA-binding activity in vitro,
with an IC50 value of 6.8 ± 0.8 [iM (Fig. 24), and preferentially
inhibits Stat3-Stat3, over Statl-Stat3, Statl-Statl, or Stat5-Stat5
DNA-binding activity (Fig. 2B), as measured by EMSA analysis
(9, 11, 17). BP-1-102 is substantially improved over the lead, S3I201.1066 (SPR, KD of 2.7 [iM; FP, IG>0 of 23 цМ; EMSA, IQ0 of
36 jiM) (17).
BP-1-102 inhibited constitutive Stat3 DNA-binding activity
(Fig. 2 С and Fig. S24), Tyr705 phosphorylation (Fig. 2 D and E ,
and Fig. S2 B, pYStat3), and Stat3-dependent luciferase reporter
(pLucTKS3) (19, 20) induction (Fig. S2C, TKS3). The inhibition
occurs in a dose- and time-dependent manner and as early as 30
min (Fig. 2 С and D and Fig. S2 B). Stat3 is distributed in the
cytoplasm, nucleus, and mitochondria (Fig. 2D and Fig. S2 D and
E). Levels of pY705Stat3 are higher in the nucleus than in the
cytoplasm, except in DUI 45 cells (Fig. S2 D and E ), and are
undetectable in mitochondria (Fig. S2£). BP-1-102 treatment attenuated both nuclear and cytoplasmic pY705Stat3 (Fig. 2 D and
Fig. S2E). By contrast, BP-1-102 had little or no effect on phospho-Shc, Src, Jak-1/2, Erkl/2, or Akt levels (Fig. 2 E), induction
of the Stat3-independent luciferase reporter, pLucSRE, which is
driven by the serum-response element (SRE)/c-fos promoter (19,
20) (Fig. S2C, SRE), or the phosphorylation of many cellular
kinases (Table SI). BP-1-102 treatment further suppressed c-Myc,
Cyclin Dl, Bcl-xL, Survivin, and VEGF expression (Fig. 2 F),
which occurred subsequent to Stat3 inhibition (Fig. 2D). Thus,
inhibition of aberrantly active Stat3 suppresses Stat3-dependent
gene regulation.
BP-1-102 Selectively Suppresses Growth, Survival, Malignant Transformation, Migration, and Invasion of Malignant Cells Harboring Consti-

tutively Active Stat3. Consistent with the dependency on abnormal

Stat3 signaling of NIH 3T3/v-Src fibroblasts and malignant cells

Fig. 2. BP-1-102 inhibits Stat3 activation. ( A and B) EMSA analysis of nuclear
extracts of equal total protein containing activated STATs, preincubated with
0-20 (iM BP-1-102 for 30 min before incubation with a radiolabeled (A and B,
/') hSIE probe that binds Stati and Stat3 or ( В , /'/') mammary gland factor el-

ement probe that binds Stat5. (C) EMSA analysis using an hSIE probe for
Stat3 DNA-binding activity in nuclear extracts of equal total protein prepared from the designated tumor cells treated with 0-20 |iM BP-1-102. ( D-F )

Immunoblots of pY705Stat3, Stat3, histone deacetylase 1 (HDAC1), pY239/
240Shc, She, pY1 022/1 023Jak1, Jak, pY1 007/1 008Jak2, Jak2, p416Src, Src,
pT202/Y204Erk1/2, Erk1/2, pY473Akt, Akt, c-Myc, Cyclin D1, Bcl-xL, Survivin,
VEGF, or ß-actin in cytosolic (Cyto) or nuclear (Nuc) fractions or whole-cell
lysates of equal total protein prepared from (D) MDA-MB-231 cells treated
with 1 0 ^iM BP-1 -1 02 for 0-6 h, or (E and F) the indicated cells treated with 0-

20 цМ BP-1-102 for 24 h. The positions of STAT-DNA complexes or proteins in
the gels are labeled; control lanes (0) represent treatment with 0.05% DMSO.
Data are representative of three or four independent determinations.

harboring aberrantly active Stat3 for the transformed phenotype
(2, 4, 19, 20), BP-1-102 treatment suppressed cell proliferation,
anchorage-dependent and -independent growth, and colony num-

bers of NIH 3T3/v-Src (v-Src), MDA-MB-231 (231), Panc-1,

DU145, and A549 cells harboring aberrantly active Stat3 (Fig. ЗА

and Fig. S3 A and B). Overexpression of the artificially engi-

neered, constitutively active Stat3C mutant (21) rendered MDAMB-231 cells refractory to BP-1-102 (Fig. ЗА, 231/St3C). Stat3C

expressed in cells is insensitive to BP-1-102 (Fig. S2F). Moreover, BP-1-102 induced apoptosis in MDA-MB-231 cells (Fig.

3 B, Eower , bars 3 and 4), which was attenuated (Fig. 35, Lower ,
bars 6 and 7 vs. bars 3 and 4) by overexpressing Flag-tagged Stat3
SH2 domain (Fig. 3B, Upper , immunoblot), the target for BP-1102. The data together show the specificity of BP-1-102 effects

against Stat3-dependent tumor cells, which are dependent on

disrupting Stat3 SH2 domain function. Treatment with BP-1-102
for 16 h, before observing the effect on proliferation (Fig. S3/4,

Insets), inhibited migration (Fig. 3C and Fig. S3C) and in-

9624 I www.pnas.org/cgi/doi/10.1073/pnas.1121606109 Zhang et al.
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ular events that promote tumor progression. BP-l-102-treated
breast cancer MDA-MB-231 cells showed decreased phosphorylation of paxillin and FAK and increased E-cadherin expression
(Fig. 3 E). To exclude nonspecific effects, ovarian cancer A2780S
cells that do not harbor aberrantly active Stat3 were treated with

BP-1-102. No changes in p-FAK or p-paxillin levels were observed (Fig. 3 E). The data that Stat3 inhibition occurs as early as
30 min (Fig. 2D), when FAK and paxillin are little affected (Fig.

S4), suggest that the decreased p-FAK and p-paxillin levels at
24 h (Fig. 3 E) are secondary events to Stat3 inhibition. BP-1-102
further suppressed Snail expression (Fig. 3 E), a Stat3-regulated
gene that controls E-cadherin expression.

Fig. 3. BP-1-102 induces antitumor cell effects in vitro and suppresses tumor-supporting factors. (A) Cultured MDA-MB-231, DU145, Panc-1, and NIH
3T3/v-Src cells harboring aberrantly active Stat3 and NIH 3T3, NIH 3T3/vRas, mouse thymus stromal epithelial cells, TE-71, Stat3-null mouse embry-

onic fibroblasts (Stat3~/_ MEFs), cisplatin-sensitive ovarian cancer cells,
A2780S cells that do not, were treated once with 0-30 цМ BP-1-102 and subjected to CyQUANT cell proliferation assay. ( В ) Annexin V/flow cytometry
analysis of MDA-MB-231 cells transfected with pcDNA-3 (mock) or Flagtagged Stat3 (St3) SH2 domain and treated with 0-15 цМ BP-1-102 (Lower);
Flag immunoblot (Upper). (C) Cultured malignant cells were treated with BP1-102, wounded, and allowed to migrate into a denuded area. (D) Number
of invaded MDA-MB-231 cells in a BioCoat invasion chamber assay and the
effects of BP-1-102. (E and F) Imm'unoblotting analysis of whole-cell lysates
prepared from MDA-MB-231 cells (E and F, i) treated with 0-15 цМ BP-1-102
or (F, ii) transfected with control (-) or Stat3 siRNA (+) and probing for FAK,
pY576/577FAK, paxillin, pY1 18paxillin, E-cadherin, Snail, KLF8, EPSTI1, or

ß-actin. (G) Number of invaded MDA-MB-231 cells in a BioCoat invasion
chamber assay and the impact of KLF8 overexpression on BP-1-102 effects.
(H-J) Immunoblotting analysis of (H) whole-cell (WC), nuclear (Nuc), or cytosolic (Cyto) lysates, (I) immunecomplexes of Stat3 (Upper) or RelA (Lower)

prepared from MDA-MB-231 cells treated with 0-15 цМ BP-1-102, or (J)
whole-cell lysates of MDA-MB-231 cells transfected with control (-) or Stat3
siRNA (+) and probing for pY705Stat3, Stat3, pS536RelA, RelA, ß-actin, or
HDAC1. (K) G-CSF, sICAM, and MIF/GIF levels assayed in conditioned medium

FAK promotes Krüppel-like factor (KLF)8 induction (23).
KLF8 and the tumor-stroma interaction factor, epithelial-stromal interaction 1 (EPSTI1) protein, promote tumor cell spread
and invasiveness (24, 25). BP-l-102-treated breast cancer cells
showed reduced KLF8 and EPSTI1 levels (Fig. 3 F, /), which was
validated by Stat3 knockdown by siRNA (Fig. 3 F, ii). Furthermore, in normal NIH 3T3 fibroblasts, transiently cotransfected
with the KLF8 promoter-driven luciferase reporter (pLucKLF8)
and v-Src vector, the activation of Stat3 by v-Src (20) induced
plucKLF8 expression by over twofold, which was repressed by
BP-1-102 (Fig. S5/4). The KLF8 promoter has three putative
Stat3 binding sites (Fig. S5 B, i). Site-specific mutation in the
nucleotide sequence -253/-245 (site 1) severely impaired the
mutant pLucKLF8/-253T/G reporter induction (Fig. S5A, compare bars 2 and 5). In vitro DNA-binding/EMSA analysis further
showed a strong Stat3 binding to an oligonucleotide probe incorporating site 1 (-253/-245), compared with the standard highaffinity ш-inducible element (hSIE) probe, which was diminished
by blocking anti-Stat3 antibody in a supershift assay (Fig. S5 B,
ii). No Stat3 binding was observed to site 2 or 3 (Fig. S5 B, ii),
although we do not exclude the possibility they contribute to Stat3

responsiveness. Thus, Stat3 directly induces the KLF8 gene.

To further study KLF8 importance, we evaluated BP-1-102
effects on cell motility and invasiveness in a KLF8 overexpression
or knockdown background. By contrast to inhibition of invasive-

ness of the wild-type cells (Fig. 3 D and G, bar 2), KLF8 overexpression (24) in MDA-MB-231 cells abolished BP-1-102 effects
(Fig. 3 G, bars 3-5). Further, studies using tetracycline-inducible
KLF8 shRNA (24) in MDA-MB-23 1-K8ikd cells show that KLF8
knockdown, as expected, suppressed cell migration (Fig. S5C,
compare bar 2 vs. 5) and invasiveness (Fig. S5D, compare bar
2 vs. 5) and in turn minimized the BP-l-102-induced effect
that is otherwise observed in the wild-type, uninduced cells (Fig.
S5 С and D, compare the relative change between bars 2 and 3 to
>
that of bars 5 and 6). Thus, KLF8 expression is one of the unо

о

derlying mechanisms of Stat3-mediated tumor cell migration and
о
-i

invasiveness.

и

<

2

from cultures of MDA-MB-231 cells treated for 48 h with BP-1-102. Positions

ее

<

BP-1-102 Represses Stat3-NF-icB Cross-Talk and the ExtracellularX
of proteins in the gel are shown. Data are representative of three or four
of Soluble Factors. Stat3 cross-talks with factors such
independent determinations. Values, mean ± SD, n = 4 or 9. *P < 0.05, **PProduction
<

0.01, ***P< 0.005.

о.

as NF-kB in the tumor microenvironment (6, 7) that redirect
inflammation signal for oncogenic functions. BP-l-102-mediated
attenuation of nuclear and cytoplasmic pY705Stat3 and of nu-

vasiveness (Fig. 3D and Fig. S3D) of Stat3-dependent tumor
clear total Stat3 led to decreased nuclear pRelA and total RelA
cells. By contrast, BP-1-102 had little or no similar antitumorlevels
cell (Fig. ЗЯ), whereas cytoplasmic RelA and pRelA levels
effects on a range of nontarget cells, including normal NIH appeared
3T3
unchanged. To investigate the concurrent decline in
(3T3), mouse thymus stromal epithelial cells, TE-71, Stat3-null
nuclear RelA, we focused on the pStat3-pRelA complex (26),

mouse embryonic fibroblasts (-/-MEFs), NIH 3T3/v-Ras (v-Ras),
which is detected in the nucleus by coimmunoprecipitation analor A2780S cells that do not harbor aberrantly active Stat3 (Fig.
3 (Fig. 3/, lane 1) and as colocalization in immunofluorescence/
ysis
A and С and Fig. S3 A-C). These effects are consistent withconfocal
the
microscopy (Fig. S&4, control, merged). BP-1-102 treatdiminished the pStat3-pRelA interaction (Fig. 3/, lane 2
down-regulation of known Stat3-inducible genes (Fig. 2 F) (1, 3, ment
4).
and Fig. S6/4, compare 25 jiM, 16 h to control), which was valBP-1-102 Modulates Factors That Regulate Cell Adhesion, Cell-Cell
idated by Stat3 knockdown by siRNA (Fig. 3 J). By contrast, BPInteractions, Motility, Migration, and Invasion. Except for Stat31-102
as- treatment had no effect on IicB-RelA interactions (Fig.

sociation with phospho-paxillin, focal adhesion kinase (FAK),
S6 B). Per the published report (26) that nuclear Stat3-NF-KB
complex promotes nuclear NF-кВ retention, BP-l-102-mediated
and Src (22), little is known about the Stat3-dependent molecZhang et al. PNAS | June 12, 2012 | vol.109 | no. 24 | 9625
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inhibition of activated Stat3 diminishes nuclear Stat3 that in turn

down-regulates nuclear pNF-кВ.

(Serpine 1), and interleukin 1 receptor antagonist (IL-1RA) production (Fig. S8D), whereas G-CSF was undetectable.

To explore further the BP- 1-102 effect on Stat3 cross- talks, we

BP-1-102 Is Detectable at Micromolar Concentrations in Plasma and in

examined the production of soluble factors by tumor cells. Cul-

ture medium from BP-l-102-treated MDA-MB-231 cells showed

Micrograms in Tumor Tissues. In vivo pharmacokinetic profiling of

lower granulocyte colony-stimulating factor (G-CSF), solubleplasma
in- samples from a cohort of three mice collected at 15, 30,
60, 90, 180, and 360 min post-i.v. treatment (3 mg/kg) with a
tercellular adhesion molecule (sICAM) 1, and macrophage migrasingle dose showed BP-1-102 levels upward of 35 'iM at 15 min
tion-inhibitory factor (MIF)/glycosylation-inhibiting factor (GIF)
postdosing, which declined by 30 min to a steady 5-10 цМ level
levels (Fig. ЪК). Moreover, treatment of cells with exogenous G-

for up to 6 h (Fig. AD, i), whereas plasma samples post-oral
CSF further induced Stat3 and RelA phosphorylation above
dosing at 3 mg/kg showed peak BP-1-102 levels of about 30 цМ
constitutive levels (Fig. S6C, compare lanes 1 and 3) and conseat 30 min, which steadily declined to 5-10 |iM over a 6-h period
quently blocked the BP-l-102-repressive effect (Fig. S6C, com(Fig. AD, ii). Thus, blood levels over a prolonged period can
pare lanes 2 and 4). Thus, BP-1-102 inhibits the production
of the IC5o values against Stat3. Moreover, BP-1-102 was
exceed

soluble factors by tumor cells.

detectable at 55 or 32 [ig/g tumor tissue, respectively, for i.v. or

oral delivery of 3 mg/kg, 15 min after the last dosing, and at 25
BP-1-102 Inhibits Growth of Human Breast and Non-Small-Cell Lung
or 15 j-ig/g tumor tissue, respectively, for i.v. or oral delivery of
Tumor Xenografts and Modulates Stat3 Activity, Stat3 Target Genes,

3 mg/kg, 24 h after the last dosing (Fig. AE). Data together

and Soluble Factors in Vivo. BP-1-102 inhibited growth of mouse
confirm that BP-1-102 is orally bioavailable and that the agent
xenografts of human breast (MDA-MB-231) and non-small-cell
accumulates in tumor tissues at levels sufficient to inhibit aber-

lung (A549) tumors that harbor aberrantly active Stat3 when
rantly active Stat3 functions and inhibit tumor growth.
administered via i.v. (tail vein injection, 1 or 3 mg/kg, every 2 or
3 d for 15 d) (Fig. 4 A and C) or oral gavage (3 mg/kg, 100Discussion
|iL,

every day) (Fig. AB). No significant changes in body weights BP-1-102
(Fig.
is designed as a Stat3-Stat3 dimerization disruptor
S7 A and B) or obvious signs of toxicity, such as loss of appetite,
with optimized structural features to enhance inhibitory activity.
decreased activity, or lethargy, were observed during the efficacy
Stat3 binding is supported by SPR, FP, ITC, and NMR data that
study or in a separate toxicity study where animals were dosed
also show disruption of Stat3 SH2 domain-pTyr peptide inter1 or 3 mg/kg i.v. every 2 or 3 d for 21 d and monitored over 42
action.
d,
Modeling predicts it binds to the three solvent-accessible
subpockets
of the Stat3-Stat3 dimer interface (27) (Fig. IB), makas shown by body weight and gross anatomical examination
of
organs (Fig. S7 С and D). The apparent stronger antitumoring
re-hydrogen bonds in the third subpocket, and additional interactions with the charged Lys side chain via the unique pentafluosponse to oral gavage is likely due to the daily dosing.
robenzene, which contribute to increased activity. Binding at the
Analysis of tumor tissue lysates shows decreased Stat3 DNApTyr peptide binding site of the SH2 domain would disrupt prebinding activity in treated tumors (T1 and T3) compared with
existing Stat3-Stat3 dimers and block de novo Stat3 phosphorylanontreated control (Fig. SSA, Upper). Immunoblotting analysis
tion
of lysates from residual tumor tissues also showed suppression
ofat the receptor and dimer formation. The reduced nuclear
pYStat3
is the combination of diminished nuclear translocation,
pY705Stat3, c-Myc, Cyclin Dl, Bcl-xL, Survivin, and VEGF exdue to activation inhibition, and Stat3 nuclear exit upon dimer
pression that occurred in a dose-dependent manner (Fig. SSA,

disruption (28).
Lower), decreased pFAK, phospho-paxillin, KLF8, and EPSTI1
The antitumor cell effects and the in vivo efficacy of BP-1-102
levels, enhanced E-cadherin expression (Fig. S SB), and diminare consistent with thwarting Stat3's key role in tumorigenesis,
ished pRelA (Fig. S8C), compared with control tumors. Analysis

including dysregulation of gene expression leading to uncontrolled
growth, survival, and angiogenesis (2, 4). The present study iden-

of residual tumor tissue lysates (T1 and T3) also showed

suppression of sICAM- 1, MIF/GIF, serpin peptidase inhibitor,

tifies KLKF8 (24) as a Stat3 target gene that promotes motility,
clade E (nexin, plasminogen activator inhibitor type 1), member 1
migration, and invasion. Further, the induction of FAK and paxillin
phosphorylation, EPSTI1 (25) expression, and the down-regulation
of E-cadherin likely contribute to Stat3-mediated malignant pro-

gression (Fig. S9). Both KLF8 and EPSTI1 promote epithelialmesenchymal transition and tumor invasiveness and are up-regulated in invasive and metastatic tumors (24, 25), as is aberrantly
active Stat3. The induction of these events would repress epithelial
cell assembly and cadherin-based cell-cell adhesions and promote
dynamic regulation of cell-matrix adhesions that would drive tumor migration and invasiveness.
In the strong interplay of tumor cells with the microenvironment, Stat3 modulates inflammatory cytokines/chemokines that
in turn suppress immune and inflammatory cells' functions and
tumor-immune surveillance (6). Of the factors regulated by Stat3

(5), IL-6, VEGF, and NF-кВ also in turn promote Stat3 activa-

Fig. 4. Human breast and non-small-cell lung tumor xenografts andtion
the or are in cross-talks that perpetuate protumorigenic pro-

antitumor effects and in vivo pharmacokinetic properties of BP-1-102. ( cesses
A-C ) (6, 7,
Mice bearing MDA-MB-231 ( A and B) or A549 (C) tumors were administered
sICAM (29),
BP-1-102 via i.v., 1 or 3 mg/kg or vehicle (0.05% DMSO in PBS) every 2 or 3 d

26). The present study raises the possibility that
G-CSF, MIF/GIF, Serpine 1, and IL-1RA induction
support Stat3-dependent tumor processes, including angiogenor oral gavage, 3 mg/kg or vehicle (0.05% DMSO) every day. Tumor sizes,
esis (30) (Fig. S9); MIF is overexpressed in breast cancer (31)
measured every 2 or 3 d, were converted to tumor volumes and plotted
and promotes disease progression (32), Serpine 1 expression
against days of treatment. (D and E) Graphical representations of BP-1-102
correlated with advanced clear cell renal cell carcinoma and
levels in (D) plasma samples collected from mice 15-360 min post-single

promoted tumor angiogenesis and aggressiveness (33). Further,
dosing of 3 mg/kg via i.v. (/) or oral gavage (/'/'), or (£) tumor tissues extracted
IL- IRA blocked IL-l-induced antitumor cell effects in prostate
15 min or 24 h after the last dosing with 3 mg/kg, i.v. or oral gavage. Values,
mean ±<SD, n = 7-10. **P < 0.01, and ***P < 0.005.
cancer cells (34) and enhanced the proliferation (35) and growth
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of hepatic and glioblastoma cells (36), and sIL-IRA mRNA
expression correlated with lymph node and hepatic metastases in

gastric carcinoma patients (37). BP-l-102-mediated repression
of these tumor-supporting factors likely contributes to its anti-

tumor effects.

We present a unique Stat3 inhibitor, BP-1-102, that sufficiently

accumulates in tumor tissues and induces antitumor responses in
human tumor xenografts that harbor aberrantly active Stat3. The
oral bioavailability of BP-1-102 represents a substantial advancement in the discovery of small-molecule Stat3 inhibitors as unique
anticancer agents.

Cell Viability, Proliferation, Colony Survival, and Wound-Healing Assays. Studies

were performed as previously reported (17). Details are provided in SI
Materials and Methods.

Transient Transfection of Cells, Luciferase, and Apoptosis Assays. Studies were

performed as previously reported (9, 20). After seeding for 12-24 h, cells
were transfected with designated plasmid or siRNA, treated or not with BP-

1-102, and processed for luciferase, immunoblotting, or Annexin V/flow
cytometry analysis. Details of the Stat3 siRNA and studies are provided in SI
Materials and Methods.

Immunostaining with Laser-Scanning Confocal Imaging. Studies are described
in detail in SI Materials and Methods.

Materials and Methods

Cells and Reagents. NIH 3T3, NIH 3T3/v-Src, and NIH 3T3/v-Ras cells, the human

Fluorescence Polarization Assay. Assays were conducted as previously reporbreast cancer line MDA-MB-231 and counterpart expressing inducible KLF8
ted (17).
shRNA (231-K8ikd), and human prostate (DU145), non-small-cell lung (A549),
and pancreatic (Panc-1) cancer cells have all been previously reported (11,
Surface
Plasmon Resonance Analysis. Studies were performed as previously
17, 20, 24). Stat3-dependent (pLucTKS3), Stat3-independent (pLucSRE),
and
(17).
pLucKLF8 luciferase reporters, and the v-Src, ß-galactosidase, Stat3 SH2reported
domain, Stat3C, and pLVUT-tTR-KRAB-KLF8 vectors have all been reported
Cell Migration/Invasion Assays. Experiments were carried out and quantified
(9, 19-21, 23, 24). Other reagents are the Human Cytokine Array Kit (R&D

as previously reported (9, 24, 28). Details are provided in SI Materials
Systems), G-CSF (Sigma-Aldrich) used at 100 ng/mL, and Stati and Stat5
Methods.
proteins (SignalChem). Primary antibodies used were anti-Stat3, pStat3, and
pSrc,

Src, pErk1/2, Erk1/2, pJakl, Jak1, Jak2, pJak2, pShc, She, Cyclin D1, c-Myc, Bcl-

xL, Survivin, Akt, pAkt, pRelA, RelA, pFAK, FAK, phospho-paxillin, paxillin,
Cytokine Analysis. The assay is described in detail in SI Materials and Methods.

E-cadherin, HDAC1, Snail, and ß-actin (Cell Signaling Technology), VEGF
(Santa Cruz Biotechnology), Flag and EPSTI1 (Sigma-Aldrich), and KLF8 Tumor
(24).
Xenografts, Efficacy, and Pharmacokinetic Studies. Studies were perCells were grown in DMEM containing 10% (vol/vol) heat-inactivated FBS.
formed as previously reported (9, 17, 28). BP-1-102 concentrations in mouse

plasma and tumor tissue lysates were assayed using a validated analytical
Cloning and Protein Expression. Molecular cloning, expression, and purificaprocedure via HPLCy. Details are provided in SI Materials and Methods.
tion of His-tagged Stat3 have previously been reported (17). The cloning of
the pXJ-FLAG-Stat3 SH2 domain and mutant KLF8 promoter is described in
Statistical Analysis. Statistical analysis was performed on mean values using

detail in SI Materials and Methods.

Prism (GraphPad Software). The significance of differences between groups
was determined by the paired ttest at *P< 0.05, **P< 0.01, and ***p< 0.005.

Nuclear Extract Preparation, Gel Shift Assay, and Densitometrie Analysis. Studies and analysis were carried out as previously described (9, 20, 28). Details are
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Immunoprecipitation and Western Blotting Analyses. Studies were performed
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